NASDAQ:INCY - Incyte Stock Price, Price Target & More

$68.39 -0.66 (-0.96 %)

(As of 04/20/2018 10:53 AM ET)

Previous Close$69.05

Today's Range$67.7501 - $69.41

52-Week Range$61.30 - $140.11

Volume464,674 shs

Average Volume2.19 million shs

Market Capitalization$14.84 billion

P/E Ratio106.86

Dividend YieldN/A

Beta0.66

About Incyte (NASDAQ:INCY)

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:INCY

CUSIP45337C10

Webwww.incyte.com

Phone302-498-6700

Debt

Debt-to-Equity Ratio0.01%

Current Ratio4.01%

Quick Ratio3.99%

Price-To-Earnings

Trailing P/E Ratio106.86

Forward P/E Ratio-427.44

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.54 billion

Price / Sales9.43

Cash Flow$0.8487 per share

Price / Cash80.58

Book Value$7.73 per share

Price / Book8.85

Profitability

EPS (Most Recent Fiscal Year)$0.64

Net Income$-313,140,000.00

Net Margins-20.38%

Return on Equity-11.85%

Return on Assets-8.05%

Miscellaneous

Employees1,208

Outstanding Shares211,800,000

How to Become a New Pot Stock Millionaire

Incyte (NASDAQ:INCY) Frequently Asked Questions

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.54. The biopharmaceutical company earned $444.20 million during the quarter, compared to analyst estimates of $435.23 million. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. Incyte's revenue for the quarter was up 36.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.05 EPS. View Incyte's Earnings History.

When is Incyte's next earnings date?

Incyte is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Incyte.

What price target have analysts set for INCY?

22 Wall Street analysts have issued 1 year price objectives for Incyte's stock. Their predictions range from $65.00 to $174.00. On average, they expect Incyte's share price to reach $117.95 in the next year. View Analyst Ratings for Incyte.

What are Wall Street analysts saying about Incyte stock?

Here are some recent quotes from research analysts about Incyte stock:

1. According to Zacks Investment Research, "Incyte's Jakafi performance was strong in 2017 driven by patient demand. The sales guidance for 2018 was also impressive. Jakafi sales are expected to get a boost from the updated labels. Incyte expects Jakafi revenues in the range of $1.35-$1.4 billion in 2018, more than 20% growth over 2017. Meanwhile, the NDA for Olumiant was resubmitted and a potential approval will further boost the top line. Incyte’s pipeline is highly encouraging with promising immune therapies including epacadostat.. However, Incyte’s dependence on only Jakafi for growth is concerning. In addition, the recent failure of epacadostat study for the melanoma study with Keytruda was a big disappointment. Shares of the company have underperformed the industry in the last six months. Loss Estimates have narrowed ahead of the Q1 earnings results. The company has a mixed record of earnings surprises in recent quarters." (4/19/2018)
2. Cowen Inc analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)

Who are some of Incyte's key competitors?

Some companies that are related to Incyte include Iqvia (IQV), ICON (ICLR), Exelixis (EXEL), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Senomyx (SNMX).

Who are Incyte's key executives?

Incyte's management team includes the folowing people:

Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 58)
Mr. David W. Gryska, Exec. VP & CFO (Age 63)
Dr. Reid M. Huber, Exec. VP & Chief Scientific Officer (Age 46)
Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 55)
Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 51)

Has Incyte been receiving favorable news coverage?

Media coverage about INCY stock has trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Incyte earned a news sentiment score of 0.04 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.65 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $68.33.

How big of a company is Incyte?

Incyte has a market capitalization of $14.84 billion and generates $1.54 billion in revenue each year. The biopharmaceutical company earns $-313,140,000.00 in net income (profit) each year or $0.64 on an earnings per share basis. Incyte employs 1,208 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

MarketBeat Community Rating for Incyte (INCY)

Community Ranking:		3.7 out of 5 ( )
Outperform Votes:		873 (Vote Outperform)
Underperform Votes:		322 (Vote Underperform)
Total Votes:		1,195

MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Incyte (NASDAQ:INCY) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

22 Wall Street analysts have issued ratings and price targets for Incyte in the last 12 months. Their average twelve-month price target is $117.95, suggesting that the stock has a possible upside of 72.47%. The high price target for INCY is $174.00 and the low price target for INCY is $65.00. There are currently 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.68	2.73	2.74	2.78
Ratings Breakdown:	0 Sell Rating(s) 7 Hold Rating(s) 15 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 18 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$117.95	$142.3684	$143.3333	$144.5238
Price Target Upside:	72.47% upside	64.45% upside	42.07% upside	27.26% upside

Incyte (NASDAQ:INCY) Consensus Price Target History

Price Target History for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Credit Suisse Group	Set Price Target	Buy	$78.00	Low
4/12/2018	UBS	Upgrade	Neutral -> Buy	$76.00	Low
4/9/2018	JPMorgan Chase	Lower Price Target	Overweight -> Overweight	$149.00 -> $96.00	Low
4/9/2018	Morgan Stanley	Lower Price Target	Overweight -> Overweight	$142.00 -> $76.00	High
4/9/2018	Gabelli	Downgrade	Buy -> Hold		Medium
4/9/2018	Nomura	Lower Price Target	Buy	$102.00	Low
4/9/2018	Oppenheimer	Set Price Target	Hold	$110.00 -> $65.00	Low
4/6/2018	SunTrust Banks	Reiterated Rating	Buy	$80.00	Low
4/6/2018	Raymond James	Set Price Target	Buy	$85.00	High
4/6/2018	Guggenheim	Reiterated Rating	Buy -> Neutral		High
4/6/2018	William Blair	Reiterated Rating	Outperform -> Market Perform		High
4/5/2018	Barclays	Lower Price Target	Overweight -> Overweight	$165.00 -> $135.00	Low
1/3/2018	BMO Capital Markets	Reiterated Rating	Buy	$172.00	Low
1/2/2018	Citigroup	Reiterated Rating	Market Perform	$135.00 -> $120.00	High
1/2/2018	Royal Bank of Canada	Upgrade	Sector Perform -> Outperform	$136.00	High
12/12/2017	Deutsche Bank	Initiated Coverage	Hold	$106.00	Medium
12/5/2017	Cowen	Reiterated Rating	Buy		Low
10/6/2017	Goldman Sachs	Initiated Coverage	Buy	$160.00	N/A
10/6/2017	Jefferies Group	Reiterated Rating	Buy		N/A
9/13/2017	Argus	Reiterated Rating	Buy	$150.00	Low
8/16/2017	Evercore ISI	Initiated Coverage	In -> In-Line	$135.00	Medium
5/31/2017	CIBC	Boost Price Target	Outperform	$125.00 -> $135.00	Low
4/17/2017	Piper Jaffray	Reiterated Rating	Overweight -> Neutral	$124.00	Medium
3/1/2017	Instinet	Initiated Coverage	Buy -> Buy	$148.00	N/A
1/18/2017	JMP Securities	Reiterated Rating	Outperform	$130.00	N/A
11/20/2016	Leerink Swann	Reiterated Rating	Outperform	$101.00 -> $115.00	N/A
6/6/2016	Brean Capital	Reiterated Rating	Buy		N/A

(Data available from 4/20/2016 forward)

Incyte (NASDAQ:INCY) Earnings History and Estimates Chart

Earnings by Quarter for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) Earnings Estimates

2018 EPS Consensus Estimate: $0.22
2019 EPS Consensus Estimate: $0.20

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	($0.33)	$0.10	($0.17)
Q2 2018	4	($0.06)	$0.39	$0.10
Q3 2018	3	$0.04	$0.47	$0.22
Q4 2018	4	($0.12)	$0.33	$0.07
Q1 2019	1	($0.05)	($0.05)	($0.05)
Q2 2019	1	$0.20	$0.20	$0.20
Q3 2019	1	$0.14	$0.14	$0.14
Q4 2019	1	($0.09)	($0.09)	($0.09)

Incyte (NASDAQ INCY) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018		($0.06)					N/A
2/15/2018	Q4 2017	($0.52)	$0.02	$435.23 million	$444.20 million	View	N/A
10/31/2017	Q3 2017	$0.06	$0.17	$360.34 million	$381.50 million	View	N/A
8/1/2017	Q2 2017	($0.05)	($0.06)	$318.45 million	$326.40 million	View	Listen
5/4/2017	Q1 2017	($0.97)	($0.96)	$359.19 million	$384.08 million	View	Listen
2/14/2017	Q416	$0.14	$0.05	$324.90 million	$326.00 million	View	Listen
11/1/2016	Q316	($0.04)	$0.11	$260.98 million	$269.50 million	View	N/A
8/9/2016	Q216	($0.02)	$0.18	$236.91 million	$208.00 million	View	N/A
5/9/2016	Q116	$0.29	$0.12	$266.38 million	$263.00 million	View	N/A
2/11/2016	Q415	$0.09	$0.29	$223.54 million	$243.88 million	View	Listen
11/3/2015	Q315	($0.41)	($0.22)	$179.30 million	$187.70 million	View	N/A
8/4/2015	Q215	($0.11)	($0.04)	$153.27 million	$162.98 million	View	Listen
4/30/2015	Q115	($0.06)	($0.11)	$155.21 million	$159.30 million	View	Listen
2/12/2015	Q414	($0.14)	($0.22)	$138.37 million	$106.00 million	View	Listen
10/30/2014	Q3	$0.02	$0.33	$149.92 million	$198.15 million	View	Listen
7/31/2014	Q214	($0.09)	($0.22)	$140.72 million	$99.58 million	View	Listen
5/1/2014	Q114	($0.19)	($0.21)	$97.70 million	$89.80 million	View	Listen
2/12/2014	Q413	($0.10)	($0.15)	$98.04 million	$97.10 million	View	Listen
10/31/2013	Q313	($0.13)	($0.14)	$81.40 million	$85.10 million	View	Listen
8/1/2013	Q2 2013	$0.08	$0.05	$114.34 million	$101.70 million	View	Listen
5/2/2013	Q1 2013	($0.18)	($0.12)	$68.16 million	$71.10 million	View	Listen
2/14/2013	Q4 2012	($0.02)	$0.14	$92.03 million	$113.80 million	View	Listen
11/1/2012	Q312	($0.21)	($0.17)	$60.61 million	$60.50 million	View	N/A
8/2/2012		($0.02)	$0.03			View	N/A
4/26/2012		($0.48)	($0.36)			View	N/A
2/15/2012		($0.40)	($0.44)			View	N/A
10/27/2011		($0.43)	($0.42)			View	N/A
7/28/2011		($0.36)	($0.41)			View	N/A
5/3/2011		($0.32)	($0.21)			View	N/A
2/10/2011		$0.19	$0.26			View	N/A
11/9/2010	Q3 2010	($0.33)	($0.26)			View	N/A
8/5/2010	Q2 2010	($0.04)	$0.02			View	N/A
5/6/2010	Q1 2010	($0.31)	($0.27)			View	N/A
2/18/2010	Q4 2009	($0.35)	($0.41)			View	N/A
11/5/2009	Q3 2009	($0.41)	($0.39)			View	N/A
7/30/2009	Q2 2009	($0.41)	($0.41)			View	N/A
5/7/2009	Q1 2009	($0.42)	($0.41)			View	N/A
2/18/2009	Q4 2008	($0.47)	($0.50)			View	N/A
11/6/2008	Q3 2008	($0.50)	($0.49)			View	N/A
7/29/2008	Q2 2008	($0.50)	($0.54)			View	N/A
4/30/2008	Q1 2008	($0.47)	($0.48)			View	N/A
2/14/2008	Q4 2007	($0.25)	($0.26)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Incyte (NASDAQ:INCY) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Incyte (NASDAQ INCY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.20%
Institutional Ownership Percentage: 93.56%

Insider Trading History for Incyte (NASDAQ:INCY)

Incyte (NASDAQ INCY) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2018	David W Gryska	Insider	Sell	1,952	$85.56	$167,013.12	12,922
2/21/2018	Reid M Huber	EVP	Sell	1,958	$85.55	$167,506.90
1/5/2018	David W Gryska	Insider	Sell	6,760	$98.87	$668,361.20	20,752
1/2/2018	Vijay K Iyengar	EVP	Sell	5,000	$97.26	$486,300.00
12/1/2017	Reid M Huber	EVP	Sell	696	$98.01	$68,214.96
11/16/2017	Paul A Friedman	Director	Sell	28,507	$105.24	$3,000,076.68
11/2/2017	David W Gryska	Insider	Sell	3,915	$105.63	$413,541.45
9/18/2017	Herve Hoppenot	President	Sell	70,502	$119.45	$8,421,463.90
9/14/2017	Barry P Flannelly	EVP	Sell	714	$124.25	$88,714.50	15,496
9/8/2017	Bros. Advisors Lp Baker	Director	Buy	100,000	$132.00	$13,200,000.00
9/5/2017	Paul Trower	Insider	Sell	3,000	$138.41	$415,230.00	14,853
9/1/2017	Eric H Siegel	EVP	Sell	1,820	$137.40	$250,068.00	23,553
8/31/2017	Paula J Swain	EVP	Sell	20,000	$140.00	$2,800,000.00	55,067
8/29/2017	Steven H Stein	EVP	Sell	2,111	$125.00	$263,875.00	18,687
8/4/2017	Paul Trower	Insider	Sell	3,000	$125.25	$375,750.00	11,853
8/1/2017	Eric H Siegel	EVP	Sell	1,820	$132.92	$241,914.40	23,553
7/20/2017	Steven H Stein	EVP	Sell	6,485	$131.09	$850,118.65	19,356
7/5/2017	Paul Trower	Insider	Sell	3,000	$126.18	$378,540.00	12,148
7/3/2017	Eric H Siegel	EVP	Sell	1,820	$126.20	$229,684.00	20,036
6/30/2017	David W Gryska	Insider	Sell	599	$129.74	$77,714.26	19,614
6/20/2017	Steven H Stein	EVP	Sell	9,883	$125.00	$1,235,375.00	18,518
6/12/2017	David W Gryska	CFO	Sell	16,756	$116.60	$1,953,749.60	35,771
6/5/2017	Paul Trower	Insider	Sell	3,000	$132.50	$397,500.00	13,950
6/1/2017	Eric H Siegel	EVP	Sell	1,820	$130.00	$236,600.00	18,744
5/31/2017	Jean Jacques Bienaime	Director	Buy	500	$131.80	$65,900.00	4,677
5/15/2017	Jean Jacques Bienaime	Director	Buy	500	$115.00	$57,500.00	4,177
5/8/2017	Reid M Huber	EVP	Sell	8,577	$119.21	$1,022,464.17	44,614
5/1/2017	Eric H Siegel	EVP	Sell	1,820	$124.73	$227,008.60	18,744
4/28/2017	Jean Jacques Bienaime	Director	Buy	500	$124.26	$62,130.00	3,677
4/13/2017	Jean Jacques Bienaime	Director	Buy	1,000	$139.66	$139,660.00	3,177
4/10/2017	David W Gryska	Insider	Sell	41,528	$138.00	$5,730,864.00	20,754
4/10/2017	Eric H Siegel	EVP	Sell	4,043	$140.18	$566,747.74	19,008
4/7/2017	Jean Jacques Bienaime	Director	Buy	1,000	$139.48	$139,480.00	2,177
4/7/2017	Steven H Stein	EVP	Sell	32,000	$137.88	$4,412,160.00	41,648
3/17/2017	Paul A Friedman	Director	Sell	50,000	$148.72	$7,436,000.00	302,976
1/9/2017	Reid M. Huber	EVP	Sell	11,739	$113.55	$1,332,963.45
11/9/2016	Reid M. Huber	EVP	Sell	2,715	$109.95	$298,514.25
10/20/2016	Paula J Swain	EVP	Sell	10,000	$90.00	$900,000.00	39,248
10/7/2016	Barry P Flannelly	EVP	Sell	24,204	$97.00	$2,347,788.00	13,595
9/23/2016	Paula J Swain	EVP	Sell	20,000	$90.00	$1,800,000.00	49,248
8/2/2016	Reid M. Huber	EVP	Sell	10,000	$87.96	$879,600.00
7/29/2016	Paula J Swain	EVP	Sell	60,000	$90.00	$5,400,000.00	89,248
3/17/2016	Julian Baker	Director	Buy	800,000	$63.98	$51,184,000.00	58,632
2/25/2016	Julian Baker	Director	Buy	64,290	$70.79	$4,551,089.10
2/16/2016	Julian Baker	Director	Buy	887,165	$69.87	$61,986,218.55
2/12/2016	Julian Baker	Director	Buy	2,251,427	$63.53	$143,033,157.31
1/15/2016	Paula J. Swain	EVP	Sell	13,531	$76.96	$1,041,345.76	23,693
1/6/2016	Richard S. Levy	EVP	Sell	3,937	$101.86	$401,022.82	16,926
12/7/2015	Richard S. Levy	EVP	Sell	3,937	$106.18	$418,030.66	16,926
11/18/2015	Paul A. Friedman	Director	Sell	225,000	$113.83	$25,611,750.00	297,518
11/10/2015	Eric H. Siegel	EVP	Sell	2,222	$104.86	$232,998.92	3,710
11/6/2015	Richard S. Levy	EVP	Sell	3,936	$116.51	$458,583.36	16,926
11/3/2015	Yao Wenqing	EVP	Sell	5,786	$124.78	$721,977.08	21,371
10/13/2015	Eric H. Siegel	EVP	Sell	2,222	$101.49	$225,510.78	3,355
10/6/2015	Richard S. Levy	EVP	Sell	3,937	$122.29	$481,455.73	16,926
9/21/2015	Reid M. Huber	EVP	Sell	10,000	$124.29	$1,242,900.00	62,865
9/16/2015	Eric H. Siegel	EVP	Sell	2,222	$130.69	$290,393.18	3,355
9/11/2015	Richard S Levy	EVP	Sell	4,301	$130.00	$559,130.00	16,926
9/8/2015	Richard S. Levy	EVP	Sell	3,937	$118.90	$468,109.30	21,227
8/13/2015	Eric H Siegel	EVP	Sell	2,222	$107.69	$239,287.18
7/15/2015	Richard S Levy	EVP	Sell	70,217	$120.00	$8,426,040.00
7/14/2015	Eric H Siegel	EVP	Sell	2,222	$113.61	$252,441.42
7/6/2015	Richard S Levy	EVP	Sell	3,937	$107.00	$421,259.00
6/23/2015	James M Daly	EVP	Sell	11,691	$108.24	$1,265,433.84
6/19/2015	Richard S Levy	EVP	Sell	20,000	$108.13	$2,162,600.00
6/12/2015	Eric H Siegel	EVP	Sell	2,223	$105.31	$234,104.13
6/8/2015	Richard S Levy	EVP	Sell	3,937	$107.58	$423,542.46
5/27/2015	Paul A Friedman	Director	Sell	196,751	$107.23	$21,097,609.73
5/22/2015	Paul A Friedman	Director	Sell	102,243	$108.22	$11,064,737.46
5/14/2015	Eric H Siegel	EVP	Sell	2,222	$104.99	$233,287.78
4/23/2015	James M Daly	EVP	Sell	36,941	$107.67	$3,977,437.47
4/17/2015	Yao Wenqing	EVP	Sell	7,150	$102.04	$729,586.00
4/14/2015	Eric H Siegel	EVP	Sell	2,222	$98.72	$219,355.84
4/13/2015	Yao Wenqing	EVP	Sell	23,000	$95.18	$2,189,140.00
4/7/2015	Yao Wenqing	EVP	Sell	20,031	$90.13	$1,805,394.03
3/30/2015	Laurent Chardonnet	VP	Sell	113,776	$93.64	$10,653,984.64
3/30/2015	Reid M Huber	EVP	Sell	34,263	$93.66	$3,209,072.58
3/12/2015	Barry A Ariko	Director	Sell	80,000	$89.27	$7,141,600.00
3/12/2015	Eric H Siegel	EVP	Sell	2,222	$89.72	$199,357.84
2/25/2015	Eric H Siegel	EVP	Sell	13,333	$85.00	$1,133,305.00
2/24/2015	James M Daly	EVP	Sell	11,112	$82.19	$913,295.28
2/17/2015	Paula J Swain	EVP	Sell	17,500	$76.90	$1,345,750.00
1/26/2015	Eric H Siegel	EVP	Sell	13,542	$79.85	$1,081,328.70
1/23/2015	James M Daly	EVP	Sell	11,109	$77.68	$862,947.12
1/20/2015	Paula J Swain	EVP	Sell	17,500	$74.17	$1,297,975.00
1/16/2015	Richard S Levy	EVP	Sell	12,000	$73.07	$876,840.00
1/8/2015	Eric H Siegel	EVP	Sell	15,626	$75.00	$1,171,950.00
1/6/2015	Richard S Levy	EVP	Sell	25,000	$71.84	$1,796,000.00
1/5/2015	Paula J Swain	EVP	Sell	17,500	$73.90	$1,293,250.00
12/23/2014	James M Daly	EVP	Sell	11,113	$74.43	$827,140.59
12/2/2014	Schutter Richard U De	Chairman	Sell	50,000	$74.89	$3,744,500.00
11/6/2014	Paul A Friedman	Director	Sell	185,653	$67.87	$12,600,269.11
10/23/2014	James M Daly	EVP	Sell	11,111	$53.49	$594,327.39
9/23/2014	James M Daly	EVP	Sell	11,111	$47.65	$529,439.15
9/16/2014	Richard S Levy	EVP	Sell	8,000	$47.58	$380,640.00
8/18/2014	Richard S Levy	EVP	Sell	8,000	$51.97	$415,760.00
7/23/2014	James M Daly	EVP	Sell	11,111	$48.54	$539,327.94
7/16/2014	Richard S Levy	EVP	Sell	8,000	$48.15	$385,200.00
6/23/2014	James M Daly	EVP	Sell	11,111	$56.03	$622,549.33
6/16/2014	Richard S Levy	EVP	Sell	8,000	$53.88	$431,040.00
6/5/2014	David C Hastings	CFO	Sell	200,000	$52.73	$10,546,000.00
5/23/2014	James M Daly	EVP	Sell	11,111	$48.48	$538,661.28
5/16/2014	Richard Levy	EVP	Sell	8,000	$50.68	$405,440.00	4,301
5/2/2014	Laurent Chardonnet	VP	Sell	34,000	$51.55	$1,752,700.00	3,811
4/23/2014	James Daly	EVP	Sell	30,555	$47.71	$1,457,779.05
2/20/2014	Paul Friedman	Director	Sell	33,354	$63.51	$2,118,312.54	417,518
2/19/2014	Paul Friedman	Director	Sell	771,182	$65.65	$50,628,098.30	417,518
2/19/2014	Schutter Richard De	Chairman	Sell	50,000	$65.53	$3,276,500.00	155,000
2/18/2014	David Hastings	CFO	Sell	275,000	$65.86	$18,111,500.00	8,500
9/10/2013	Paul A Friedman	CEO	Sell	376,789	$37.32	$14,061,765.48
9/9/2013	Laurent Chardonnet	VP	Sell	44,834	$37.31	$1,672,756.54
9/6/2013	David C Hastings	CFO	Sell	100,000	$35.16	$3,516,000.00
9/6/2013	Richard S Levy	EVP	Sell	25,000	$35.28	$882,000.00
9/5/2013	Paula J Swain	EVP	Sell	94,444	$35.06	$3,311,206.64
8/19/2013	Roy Whitfield	Director	Sell	50,000	$26.70	$1,335,000.00	671,082
5/17/2013	Roy A Whitfield	Director	Sell	40,000	$23.08	$923,200.00
5/13/2013	Richard S Levy	EVP	Sell	55,699	$22.30	$1,242,087.70

(Data available from 1/1/2013 forward)

Incyte (NASDAQ INCY) News Headlines

Source:

Date	Headline
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY finance.yahoo.com - April 19 at 5:34 PM
	Incyte (INCY) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 19 at 12:49 PM
	ValuEngine Lowers Incyte (INCY) to Strong Sell www.americanbankingnews.com - April 18 at 11:22 PM
	Incyte (INCY) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - April 18 at 3:31 PM
	Incyte (INCY) Given a $78.00 Price Target by Credit Suisse Group Analysts www.americanbankingnews.com - April 18 at 8:47 AM
	What's Next for Incyte? www.fool.com - April 17 at 8:39 AM
	Days After a Shocking Cancer Failure, Incyte Goes Back to Work www.bloomberg.com - April 16 at 5:17 PM
	What Incyte's Phase 3 Fail Means for Immuno-Oncology finance.yahoo.com - April 16 at 5:17 PM
	Incyte (INCY) and PRA Health Sciences (PRAH) Critical Survey www.americanbankingnews.com - April 15 at 11:15 AM
	What Happened With Incyte's IDO Inhibitor Flop www.fool.com - April 14 at 8:28 AM
	What Happened With Incyte's IDO Inhibitor Flop finance.yahoo.com - April 14 at 8:28 AM
	Industrials, airlines, energy & biotech in the blitz www.cnbc.com - April 13 at 8:29 AM
	Incyte to Report First Quarter Financial Results finance.yahoo.com - April 13 at 8:29 AM
	$387.35 Million in Sales Expected for Incyte Co. (INCY) This Quarter www.americanbankingnews.com - April 13 at 3:51 AM
	Why GoPro, Incyte, and Wynn Resorts Jumped Today finance.yahoo.com - April 12 at 5:33 PM
	Contrasting Incyte (INCY) and Syneos Health (SYNH) www.americanbankingnews.com - April 12 at 3:46 PM
	Incyte (INCY) Stock Rating Upgraded by UBS www.americanbankingnews.com - April 12 at 10:19 AM
	-$0.12 EPS Expected for Incyte Co. (INCY) This Quarter www.americanbankingnews.com - April 11 at 11:18 AM
	Is Beaten-Down Incyte Corporation Stock a Buy Now? finance.yahoo.com - April 11 at 8:36 AM
	Oppenheimer Weighs in on Incyte Co.'s Q1 2018 Earnings (INCY) www.americanbankingnews.com - April 11 at 8:05 AM
	Acadia, Incyte Show the Way to Monday's 52-Week Low Club 247wallst.com - April 10 at 8:35 AM
	Investors Buy Large Volume of Put Options on Incyte (INCY) www.americanbankingnews.com - April 10 at 7:44 AM
	Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge finance.yahoo.com - April 9 at 5:16 PM
	Incyte Cancer Drug Flop Is Costly and Likely to Be Duplicated finance.yahoo.com - April 9 at 5:16 PM
	Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial finance.yahoo.com - April 9 at 5:16 PM
	Incyte (INCY) Price Target Cut to $96.00 by Analysts at JPMorgan Chase www.americanbankingnews.com - April 9 at 11:02 AM
	Credit Suisse Group Trims Incyte (INCY) Target Price to $76.00 www.americanbankingnews.com - April 9 at 9:56 AM
	Incyte (INCY) Price Target Lowered to $76.00 at Morgan Stanley www.americanbankingnews.com - April 9 at 9:55 AM
	Incyte (INCY) Downgraded by Gabelli www.americanbankingnews.com - April 9 at 8:50 AM
	Incyte Falls After Phase 3 Flop, But The Sky Isn't Falling seekingalpha.com - April 9 at 8:26 AM
	[$$] Biotech Gets a Reality Check finance.yahoo.com - April 9 at 8:26 AM
	Today’s Research Reports on Stocks to Watch: Incyte and Merck finance.yahoo.com - April 9 at 8:26 AM
	Incyte (INCY) Price Target Lowered to $102.00 at Nomura www.americanbankingnews.com - April 9 at 8:25 AM
	Incyte (INCY) PT Set at $65.00 by Oppenheimer www.americanbankingnews.com - April 9 at 7:54 AM
	Incyte (INCY) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 7 at 10:26 AM
	Your Daily Pharma Scoop: Major Setback For Incyte, Aclaris Agreement, MannKind Offering seekingalpha.com - April 7 at 8:33 AM
	Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda www.wsj.com - April 7 at 8:33 AM
	Incyte's Horrible News Derails a Promising Class of Cancer Drugs finance.yahoo.com - April 7 at 8:33 AM
	[$$] Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck’s Keytruda finance.yahoo.com - April 7 at 8:33 AM
	Incyte (INCY) Given Buy Rating at SunTrust Banks www.americanbankingnews.com - April 6 at 9:16 PM
	The Biggest Movers: Ventas Edges Up; Incyte Plunges www.barrons.com - April 6 at 5:37 PM
	NewLink will review clinical programs after Merck, Incyte trial failure www.marketwatch.com - April 6 at 5:37 PM
	Incyte-Merck trial fails in blow to cancer immunotherapy, but researchers remain hopeful www.cnbc.com - April 6 at 5:13 PM
	Incyte (INCY) Given a $85.00 Price Target by Raymond James Financial Analysts www.americanbankingnews.com - April 6 at 2:28 PM
	Mid-Day Market Update: Dow Falls 350 Points; Incyte Shares Plunge feeds.benzinga.com - April 6 at 1:37 PM
	Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure investorplace.com - April 6 at 12:30 PM
	Incyte (INCY) Receives Neutral Rating from Guggenheim www.americanbankingnews.com - April 6 at 10:59 AM
	Incyte (INCY) Downgraded by William Blair to "Market Perform" www.americanbankingnews.com - April 6 at 10:44 AM
	Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial feeds.benzinga.com - April 6 at 9:34 AM
	Incyte, Merck shares slide after melanoma therapy fails study www.cnbc.com - April 6 at 9:17 AM

Incyte (NASDAQ:INCY) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Incyte (NASDAQ:INCY) Income Statement, Balance Sheet and Cash Flow Statement

Incyte (NASDAQ INCY) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff